KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Payables (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Payables for 8 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Payables fell 10.98% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, down 10.98% year-over-year, with the annual reading at $6.5 million for FY2025, 10.98% down from the prior year.
  • Payables hit $6.5 million in Q4 2025 for Adaptive Biotechnologies, down from $10.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $12.2 million in Q1 2024 to a low of $2.7 million in Q2 2022.
  • Historically, Payables has averaged $6.9 million across 5 years, with a median of $6.7 million in 2025.
  • Biggest five-year swings in Payables: crashed 55.36% in 2022 and later skyrocketed 236.88% in 2023.
  • Year by year, Payables stood at $3.3 million in 2021, then soared by 144.45% to $8.1 million in 2022, then fell by 4.52% to $7.7 million in 2023, then dropped by 5.88% to $7.3 million in 2024, then fell by 10.98% to $6.5 million in 2025.
  • Business Quant data shows Payables for ADPT at $6.5 million in Q4 2025, $10.3 million in Q3 2025, and $6.9 million in Q2 2025.